FYN |
FYN: Proto-oncogene tyrosine-protein kinase Fyn |
BLNK |
IPI00004549 |
3.997 |
Evidence |
|
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
HLA-C |
HLA-C, XXbac-BCX101P6.2-001: HLA class I antigen |
3.997 |
Evidence |
|
HLA-DMB |
HLA-DMB, DMB, RING7: HLA class II histocompatibility antigen, DM beta chain prec |
NULL |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-39 alpha chain precursor |
3.997 |
Evidence |
|
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
HLA-DPB1 |
HLA class II histocompatibility antigen, SB beta chain (Fragment) |
3.997 |
Evidence |
|
FYN |
FYN: Proto-oncogene tyrosine-protein kinase Fyn |
FES |
Proto-oncogene c-fes variant 3 |
3.997 |
Evidence |
|
NULL |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-67 alpha chain precursor |
HLA-DMA |
DMA, HLA-DMA, DAQB-96B10.1-001, DASS-67H14.8-001, XXbac-BCX136A3.1-001, XXbac-BP |
3.997 |
Evidence |
|
HLA-DMB |
HLA-DMB, DMB, RING7: HLA class II histocompatibility antigen, DM beta chain prec |
HLA-A |
HLA-A, HLAA: HLA class I histocompatibility antigen, A-80 alpha chain precursor |
3.997 |
Evidence |
|
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
HLA-B |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-53 alpha chain precursor |
3.997 |
Evidence |
O
|
KIT |
KIT: Mast/stem cell growth factor receptor precursor |
FES |
Proto-oncogene c-fes variant 3 |
3.997 |
Evidence |
|
HLA-B |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-81 alpha chain precursor |
HLA-DMA |
DMA, HLA-DMA, DAQB-96B10.1-001, DASS-67H14.8-001, XXbac-BCX136A3.1-001, XXbac-BP |
3.997 |
Evidence |
|
HLA-DMB |
HLA-DMB, DMB, RING7: HLA class II histocompatibility antigen, DM beta chain prec |
HLA-C |
IPI00719394 |
3.997 |
Evidence |
|
HLA-B |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-7 alpha chain precursor |
NULL |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-38 alpha chain precursor |
3.997 |
Evidence |
|
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
HLA-C |
IPI00719394 |
3.997 |
Evidence |
|
HLA-A |
HLA-A, HLAA: HLA class I histocompatibility antigen, A-11 alpha chain precursor |
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
3.997 |
Evidence |
|
HLA-G |
HLA-G, DAQB-346J13.1-002, DASS-366B6.2-002, XXbac-BCX209H21.15-002, XXbac-BPG12I |
HLA-DMA |
DMA, HLA-DMA, DAQB-96B10.1-001, DASS-67H14.8-001, XXbac-BCX136A3.1-001, XXbac-BP |
3.997 |
Evidence |
|
NULL |
HLA-B, HLAB: HLA class I histocompatibility antigen, B-50 alpha chain precursor |
B2M |
B2M, CDABP0092, HDCMA22P: Beta-2-microglobulin precursor [Contains: Beta-2-micro |
3.997 |
Evidence |
|
UBE2A |
UBE2A, RAD6A: Ubiquitin-conjugating enzyme E2 A |
UBR1 |
UBR1: E3 ubiquitin-protein ligase UBR1 |
3.995 |
Evidence |
|
RAB8A |
RAB8A: RAB8A protein |
RAB1A |
RAB1A, RAB1: Ras-related protein Rab-1A |
3.99 |
Evidence |
|
COPS6 |
COPS6, CSN6, HVIP: COP9 signalosome complex subunit 6 |
COPS8 |
COPS8, CSN8: COP9 signalosome complex subunit 8 |
3.987 |
Evidence |
|
BAK1 |
IPI00003352 |
BAD |
BAD, BBC6, BCL2L8: Bcl2 antagonist of cell death |
3.987 |
Evidence |
|
PRKCG |
PRKCG, PKCG: Protein kinase C gamma type |
PDLIM5 |
PDLIM5, ENH: PDZ and LIM domain protein 5 |
3.985 |
Evidence |
O
|
MYCN |
MYCN, NMYC: N-myc proto-oncogene protein |
MAP2K2 |
MAP2K2, MEK2, MKK2, PRKMK2: Dual specificity mitogen-activated protein kinase ki |
3.985 |
Evidence |
|
HPCAL1 |
HPCAL1, BDR1: Hippocalcin-like protein 1 |
K-ALPHA-1 |
TUBA1B: Tubulin alpha-1B chain |
3.985 |
Evidence |
|
DSTN |
DSTN, ACTDP, DSN: Destrin |
HIST2H2BE |
HIST2H2BE, H2BFQ: Histone H2B type 2-E |
3.985 |
Evidence |
|
ATXN7 |
ATXN7, SCA7: Ataxin-7 |
GTF2B |
GTF2B, TF2B, TFIIB: Transcription initiation factor IIB |
3.982 |
Evidence |
|